Cedonem
(Meropenem 0.5 / 1g Vials)
Incidence of common drug-related adverse events with antibiotic regimens in clinical trials with patients with serious bacterial infections.
| Adverse event | Meropenem (n=6308) | Cetazidime, Cefotaxime, or Ceftriaxone (n=2804). | Imipenem/Cilastatin (n=2566) | Clindamycin/ Aminoglycoside based therapy (n=527) |
|---|---|---|---|---|
| Diarrhea | 2.5 | 2.5 | 1.2 | 3,8 |
| Rash | 14. | 1.8 | 1.4 | 1.0 |
| Nausea/Vomiting | 1.2 | 0.4 | 2.8 | 1.7 |
| Headache | 0.4 | 0.1 | 0.6 | 0 |
| Injection-Site reaction | 09 | 0.6 | 1.1 | 0.2 |
| Sepsis | 0.1 | 0.6 | 0.2 | 02 |
| Pain | 0.1 | 0.2 | 0.1 | 0.2 |
| Pruritus | 0.3 | 0.2 | 0.9 | 0.6 |
| Other | 0.1 | 0 | 0.2 | 0 |
NOTE: Data are percentage of patients who experienced the adverse event. Adapted from Linden P. Safety profile of Meropenem: an updated review of over 6000 patients treated with Meropenem
Includes constipation, oral candidiasis, glossitis, hypotension, and renal failure
DOSAGE AND ADMINISTRATION
| INDICATIONS | DOSAGE (ADULT) |
|---|---|
| Skin & Skin Structure Infections | 500 mg IV q8hr; not to exceed 2 g IV q8hr |
| Intra-Abdominal Infections: | 1 g IV q8hr; not to exceed 2 g IV q8hr |
Meropenem vs Imipenem/Cilastatin
- Meropenem CSF concentration approx. those of plasma but Imipenem has low concentration.
- Meropenem free drug %T>MIC exposure was significantly greater than that of Imipenem against Enterobacteriaceae and P. aeruginosa."
- Susceptibility of Imipenem to hydrolysis by renal dehydropeptidase requires its coadministration with the renal dehydropeptidase inhibitor Cilastatin, to avoid subsequent nephrotoxicity. In contrast, this coadministration is not necessary with Meropenem because this agent are not hydrolyzed by renal dehydropeptidase.
- Comparing MIC50 and MIC90 results for all Enterobacteriaceae isolates, Meropenem was 8- to 16-fold more potent than Imipenem equal to or 2-fold more potent than Ertapenem."
- Complicated Skin and Skin-Structure Infections in patients with Diabetes Mellitus, clinical response rate was 85.6% for patients receiving Meropenem and 72.4% for those receiving Imipenem/Cilastatin."
Meropenem shows highest sensitivity against 150 isolates of Acinetobacter species"
